ORGENESIS INC. (OTCMKTS:ORGS) Files An 8-K Results of Operations and Financial Condition
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On May 9, 2019, Orgenesis Inc. (the Company) issued a press release announcing its results of operations and financial condition as well as a business update for the quarter ended March 31, 2019. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K under this heading, including the related Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth in such a filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
|99.1||Press Release of Orgenesis Inc. dated May 9, 2019.|
Orgenesis Inc. Exhibit
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Orgenesis Inc.: Exhibit 99.1 – Filed by newsfilecorp.com Orgenesis First Quarter 2019 Revenue Increases 177% to a Record $7.3 Million Company Expands Point of Care Platform; Benefits from Growing Cell and Gene Therapy Market GERMANTOWN,…
To view the full exhibit click
About ORGENESIS INC. (OTCMKTS:ORGS)
Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company’s subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine, Autologous Insulin Producing (AIP) cells, into clinical development.